Top-News

Roche Holding Aktie News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
344,20 €
+0,60 €
+0,17%
07:30:09 Uhr
Depot/Watchlist
Marktkapitalisierung *
34,95 Mrd. €
Streubesitz
16,26%
KGV
25,93
Dividende
9,70 CHF
Dividendenrendite
3,00%
Index-Zuordnung
-

Roche Holding News

22.07.25 - GlobeNewswire
Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)
Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will replace the non-​voting equity securities (Genussscheine). Reduction of the nominal ...
22.07.25 - GlobeNewswire
Roche Verwaltungsrat schlägt Umtausch von Genussscheinen in Partizipationsscheine vor
Partizipationsscheine mit einem Nennwert von je CHF 0.001 ersetzen die Genussscheine. Herabsetzung des Nennwerts der Inhaberaktien von CHF 1.00 auf CHF 0.001 je Aktie, zur ...
21.07.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease
The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was ...
07.07.25 - PR Newswire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs PR Newswire
30.06.25 - GlobeNewswire
Changes to the Roche Enlarged Corporate Executive Committee
Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche Pharma Research and Early ...
23.06.25 - GlobeNewswire
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the ...
20.06.25 - GlobeNewswire
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-​free survival - three times longer than R-GemOx 1 This well-​tolerated investigational combination ...
16.06.25 - GlobeNewswire
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-​stage Parkinson’s disease Prasinezumab is a ...
15.06.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-​risk for the use of Elevidys in non-​ambulatory patients with Duchenne has been re-​assessed, following two cases of fatal acute liver ...
04.06.25 - GlobeNewswire
Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers the same efficacy and safety ...
03.06.25 - GlobeNewswire
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First ...
31.05.25 - GlobeNewswire
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The Itovebi TM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA -mutated HR-​positive, HER2-negative advanced breast cancer, ...
30.05.25 - GlobeNewswire
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment Phase III studies for fenebrutinib ...
23.05.25 - GlobeNewswire
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
Positive recommendation based on phase III INAVO120 data showing Itovebi TM (inavolisib) in combination with palbociclib and fulvestrant more than doubled progression-​free ...
23.05.25 - GlobeNewswire
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology 1 , with an initial focus on critically ill newborns ...
23.05.25 - GlobeNewswire
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with ...
22.05.25 - GlobeNewswire
FDA approves Roche’s Susvimo for diabetic retinopathy
Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months Susvimo’s innovative ...
20.05.25 - GlobeNewswire
Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the phase III STARGLO study 1,2 There is an ...
14.05.25 - GlobeNewswire
Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis
The VENTANA MET (SP44) RxDx Assay detects the MET (also known as c-Met) protein, which is over-​expressed in some patients with non-​squamous non-small cell lung cancer ...
13.05.25 - GlobeNewswire
Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and ...

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »